We appreciate the comments from Urbiztondo and colleagues [1] on the hepatits A vaccination schedules in Spain.
From the study published by Sabrià et al. [2] emanates the following conclusion: the lower the number of doses and their content in the hepatitis A vaccination schedule, the higher the possibility to select virus variants escaping vaccine protection. However, in situations of vaccine shortage, doses and content might be reduced.
We must admit that the term vaccine failure is misleading and directly dependent on what is considered to be an optimal or suboptimal vaccine dose. The recommended schedule for the dual TWINRIX vaccine consists of three doses containing each 720 ELISA Units for adults and 360 ELISA Units for children, resulting in 2160 and 1080 ELISA Units for adults and children, respectively. However, it has been documented that a single dose of the mono HAVRIX vaccine containing 1440 ELISA units is effective in adults [3] . Accepting this latter dose as a threshold, we classified the vaccinated patients of our study in optimallyvaccinated (total dose of 1440 and 720 ELISA units for adults or children, respectively) or suboptimally-vaccinated (below the dose threshold). All patients were immunocompetent. One patient received a total dose of 720 ELISA units in his childhood and was considered to be optimally-vaccinated; two antigenic variants were selected in his virus population. This patient was HIV-non-infected and received the vaccine twenty years before the infection; he would have benefited from an analysis for serological markers and/or a booster dose. In contrast, two HIV-infected patients who received a single dose of only 720 ELISA units, around one and a half year before the infection, were considered to be suboptimally-vaccinated. Nevertheless, no antigenic variants were detected in their swarm of mutants. Finally, two additional patients received 1440 ELISA units, scheduled in two doses. One of them was HIVinfected and considered to be optimally-vaccinated, since the shots were administered two years before the infection, and no variants were detected. The second patient was HIV-non-infected and considered to be suboptimally-vaccinated, because received the shots during the incubation period; he harbored an antigenic variant at a high frequency. A single dose of 1440 ELISA Units would have been a better choice. Alternatively, rapid detection of HAV RNA in stool could have been used as a criterion to decide whether vaccination was appropriate or not.
Forced by scenarios of vaccine shortage new polices have to be adopted to avoid the spread of the outbreaks. Although globally these measures are well planned, their implementation in particular patients may not be always sufficient to prevent the selection of vaccine-escape variants.
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